|
US7973169B2
(en)
|
2003-09-06 |
2011-07-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
CN101675928A
(zh)
*
|
2003-11-14 |
2010-03-24 |
沃泰克斯药物股份有限公司 |
可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
|
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
CA2881078C
(en)
*
|
2004-06-24 |
2018-10-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
RU2008109031A
(ru)
|
2005-08-11 |
2009-09-20 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Модуляторы муковисцидозного трансмембранного регулятора проводимости
|
|
PT2404919E
(pt)
|
2005-11-08 |
2013-10-22 |
Vertex Pharma |
Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
|
|
EP2016065B1
(en)
|
2005-12-28 |
2012-09-19 |
Vertex Pharmaceuticals Incorporated |
1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
|
|
US7671221B2
(en)
*
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
LT1993360T
(lt)
|
2005-12-28 |
2017-06-12 |
Vertex Pharmaceuticals Incorporated |
N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
|
|
US7645789B2
(en)
*
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
USRE50453E1
(en)
|
2006-04-07 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
JP5420395B2
(ja)
|
2006-04-07 |
2014-02-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｐ結合カセット輸送体の調節剤
|
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
US8563573B2
(en)
*
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
|
EP2164840A2
(en)
|
2007-05-09 |
2010-03-24 |
Vertex Pharmaceuticals Incorporated |
Modulators of cftr
|
|
CA2696298C
(en)
|
2007-08-24 |
2016-09-06 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
NZ583878A
(en)
*
|
2007-09-14 |
2012-10-26 |
Vertex Pharma |
Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
|
|
CN102743385B
(zh)
|
2007-11-16 |
2014-09-17 |
沃泰克斯药物股份有限公司 |
Atp结合盒转运蛋白的异喹啉调节剂
|
|
AU2008335439A1
(en)
*
|
2007-12-07 |
2009-06-18 |
Vertex Pharmaceuticals Incorporated |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
|
CA2989620C
(en)
|
2007-12-07 |
2022-05-03 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
|
HUE049642T2
(hu)
*
|
2007-12-07 |
2020-09-28 |
Vertex Pharma |
3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
|
|
ES2422741T3
(es)
*
|
2007-12-13 |
2013-09-13 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
CA2716109C
(en)
|
2008-02-28 |
2016-07-19 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl derivatives as cftr modulators
|
|
NZ616097A
(en)
|
2008-03-31 |
2015-04-24 |
Vertex Pharma |
Pyridyl derivatives as cftr modulators
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
WO2010037066A2
(en)
*
|
2008-09-29 |
2010-04-01 |
Vertex Pharmaceuticals Incorporated |
Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
MX2011004375A
(es)
|
2008-10-23 |
2013-03-07 |
Vertex Pharma |
Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
|
|
EP2382197B1
(en)
|
2008-12-30 |
2016-10-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
SI3330255T1
(sl)
|
2009-03-20 |
2021-03-31 |
Vertex Pharmaceuticals Incorporated |
Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
ES2900353T3
(es)
|
2010-04-07 |
2022-03-16 |
Vertex Pharma |
Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
|
|
TWI549950B
(zh)
|
2010-04-07 |
2016-09-21 |
維泰克斯製藥公司 |
３－（６－（１－（２，２－二氟苯并［ｄ］［１，３］二氧雜環戊烯－５－基）環丙烷甲醯胺基）－３－甲基吡啶－２－基）苯甲酸之固體形式
|
|
RU2569678C2
(ru)
|
2010-04-22 |
2015-11-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ получения циклоалкилкарбоксамидо-индольных соединений
|
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
|
CA2852991C
(en)
|
2011-11-08 |
2019-12-31 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
NZ727015A
(en)
|
2012-01-25 |
2017-12-22 |
Vertex Pharma |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
EP2819670B1
(en)
|
2012-02-27 |
2026-05-20 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical Composition and Their Administration
|
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
AU2013290444B2
(en)
|
2012-07-16 |
2018-04-26 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
|
AU2014262636A1
(en)
*
|
2013-05-10 |
2015-11-26 |
Gilead Apollo, Llc |
ACC inhibitors and uses thereof
|
|
EA201591962A1
(ru)
|
2013-05-10 |
2016-06-30 |
Нимбус Аполло, Инк. |
Ингибиторы акк и их применение
|
|
AU2014262638A1
(en)
|
2013-05-10 |
2015-11-26 |
Gilead Apollo, Llc |
ACC inhibitors and uses thereof
|
|
EP2994128B1
(en)
|
2013-05-10 |
2019-01-30 |
Gilead Apollo, LLC |
Acc inhibitors and uses thereof
|
|
CA2930199C
(en)
|
2013-11-12 |
2022-10-25 |
Vertex Pharmaceuticals Incorporated |
Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
|
|
PL3925607T5
(pl)
|
2014-04-15 |
2026-06-01 |
Vertex Pharmaceuticals Incorporated |
Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
|
|
CA2950724A1
(en)
*
|
2014-06-03 |
2015-12-10 |
Novartis Ag |
Naphthyridinedione derivatives
|
|
CA2963945C
(en)
|
2014-10-07 |
2023-01-10 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
|
CA2966023A1
(en)
|
2014-10-31 |
2016-05-06 |
Abbvie S.A.R.L. |
Substituted tetrahydropyrans and method of use
|
|
HUE055423T2
(hu)
|
2014-11-18 |
2021-11-29 |
Vertex Pharma |
Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
|
|
US10047051B2
(en)
|
2015-06-02 |
2018-08-14 |
Abbvie S.Á.R.L. |
Substituted pyridines and method of use
|
|
US9840513B2
(en)
|
2015-07-16 |
2017-12-12 |
Abbvie S.Á.R.L. |
Substituted tricyclics and method of use
|
|
PL3359541T3
(pl)
|
2015-10-09 |
2021-01-11 |
AbbVie Overseas S.à r.l. |
N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
|
|
AU2016333855A1
(en)
|
2015-10-09 |
2018-04-26 |
AbbVie S.à.r.l. |
Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
|
|
CN108602816A
(zh)
|
2015-10-09 |
2018-09-28 |
艾伯维公司 |
用于治疗囊性纤维化的新颖化合物
|
|
AU2017256172A1
(en)
|
2016-04-26 |
2018-09-06 |
AbbVie S.à.r.l. |
Modulators of cystic fibrosis transmembrane conductance regulator protein
|
|
US10138227B2
(en)
|
2016-06-03 |
2018-11-27 |
Abbvie S.Á.R.L. |
Heteroaryl substituted pyridines and methods of use
|
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
US9981910B2
(en)
|
2016-10-07 |
2018-05-29 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
WO2018116185A1
(en)
|
2016-12-20 |
2018-06-28 |
AbbVie S.à.r.l. |
Deuterated cftr modulators and methods of use
|
|
TW201831471A
(zh)
|
2017-02-24 |
2018-09-01 |
盧森堡商艾伯維公司 |
囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
|
|
US10988454B2
(en)
|
2017-09-14 |
2021-04-27 |
Abbvie Overseas S.À.R.L. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
WO2019193062A1
(en)
|
2018-04-03 |
2019-10-10 |
Abbvie S.Á.R.L |
Substituted pyrrolidines and their use
|
|
US11345691B2
(en)
|
2019-06-03 |
2022-05-31 |
AbbVie Global Enterprises Ltd. |
Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
WO2021011327A1
(en)
|
2019-07-12 |
2021-01-21 |
Orphomed, Inc. |
Compound for treating cystic fibrosis
|
|
WO2021052797A1
(en)
|
2019-09-20 |
2021-03-25 |
Sabic Global Technologies B.V. |
Compounds for use in catalyst compositions for the production of polyolefins
|
|
MX2022005810A
(es)
|
2019-11-12 |
2022-06-08 |
Genzyme Corp |
Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente.
|
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
WO2021113808A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Cftr-modulating arylamides
|
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
US12324802B2
(en)
|
2020-11-18 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
EP4274828A1
(en)
|
2021-01-06 |
2023-11-15 |
AbbVie Global Enterprises Ltd. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
WO2022150173A1
(en)
|
2021-01-06 |
2022-07-14 |
AbbVie Global Enterprises Ltd. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
IL311038A
(en)
|
2021-09-03 |
2024-04-01 |
Genzyme Corp |
Indole compounds and methods of use
|
|
WO2023034946A1
(en)
|
2021-09-03 |
2023-03-09 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
|
WO2024054845A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocycic compounds, compositions, and methods of using thereof
|
|
IL319374A
(en)
|
2022-09-07 |
2025-05-01 |
Sionna Therapeutics Inc |
Macrocyclic compounds, compositions and methods of using them
|
|
WO2024054851A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocyclic compounds, compositions and methods of using thereof
|
|
WO2025132358A1
(en)
|
2023-12-21 |
2025-06-26 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases
|